Literature DB >> 27686672

A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia.

Takahiro Tanahashi1, Nodoka Sekiguchi2,3, Kazuyuki Matsuda4, Akihiro Matsumoto5, Toshiro Ito2, Hideyuki Nakazawa2, Fumihiro Ishida6,7,8.   

Abstract

Large granular lymphocyte leukemia (LGL-L) is defined morphologically as a group of lymphoproliferative disorders, including T-cell large granular lymphocytic leukemia (T-LGL-L), chronic lymphoproliferative disorders of NK cells (CLPD-NK), and aggressive NK cell leukemia. We investigated the morphological features of LGL leukemic cells in LGL-L patients to identify screening methods best suited to application in daily clinical practice. LGL leukemic cells were mostly indistinguishable from normal LGL; however, we developed a simplified approach to distinguishing among these cells, in which lymphocyte  % and the proportion of granular lymphocytes among lymphocytes (GL %) can serve as parameters at the cut-off values of 52 and 50 %, respectively. We confirmed the accuracy of these methods in validation groups. It may be useful to evaluate GL % to screen for LGL-L using a cut-off threshold of 50 when Lym % exceeds 52 in the peripheral blood examination in cases in which LGL-L is suspected in daily practice while keeping clinical context and the coefficient of variation of these parameters under consideration.

Entities:  

Keywords:  Cytotoxic T-cell; Granular lymphocyte; LGL; Large granular lymphocyte leukemia; NK cell

Mesh:

Year:  2016        PMID: 27686672     DOI: 10.1007/s12185-016-2092-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B.

Authors:  William G Morice; Paul J Kurtin; Ayalew Tefferi; Curtis A Hanson
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets.

Authors:  W G Morice; D Jevremovic; H Olteanu; A Roden; G Nowakowski; S Kroft; C A Hanson; P J Kurtin
Journal:  Leukemia       Date:  2010-01-28       Impact factor: 11.528

3.  Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.

Authors:  Fumihiro Ishida; Young Hyeh Ko; Won Seog Kim; Junji Suzumiya; Yasushi Isobe; Kazuo Oshimi; Shigeo Nakamura; Ritsuro Suzuki
Journal:  Cancer Sci       Date:  2012-03-23       Impact factor: 6.716

4.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 5.  Large granular lymphocytic leukaemia pathogenesis and management.

Authors:  Claire Dearden
Journal:  Br J Haematol       Date:  2010-12-15       Impact factor: 6.998

Review 6.  Clonal diseases of large granular lymphocytes.

Authors:  T P Loughran
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

7.  Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations.

Authors:  Takahiro Tanahashi; Nodoka Sekiguchi; Kazuyuki Matsuda; Yuka Takezawa; Toshiro Ito; Hikaru Kobayashi; Naoaki Ichikawa; Sayaka Nishina; Noriko Senoo; Hitoshi Sakai; Hideyuki Nakazawa; Fumihiro Ishida
Journal:  Leuk Res       Date:  2016-04-04       Impact factor: 3.156

8.  Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan.

Authors:  Shimpei Kawahara; Makoto Sasaki; Yasushi Isobe; Jun Ando; Masaaki Noguchi; Michiaki Koike; Takao Hirano; Kazuo Oshimi; Koichi Sugimoto
Journal:  Eur J Haematol       Date:  2009-01-29       Impact factor: 2.997

9.  Permanent large granular lymphocytosis in the blood of splenectomized individuals without concomitant increase of in vitro natural killer cell cytotoxicity.

Authors:  E Kelemen; P Gergely; D Lehoczky; E Triska; J Demeter; P Vargha
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

10.  T-cell large granular lymphocyte leukemia: an Asian perspective.

Authors:  Yok-Lam Kwong; Wing-Yan Au; Anskar Y H Leung; Eric W C Tse
Journal:  Ann Hematol       Date:  2010-04       Impact factor: 3.673

View more
  4 in total

1.  Immune-Enhancing Effects of Co-treatment With Kalopanax pictus Nakai Bark and Nelumbo nucifera Gaertner Leaf Extract in a Cyclophosphamide-Induced Immunosuppressed Rat Model.

Authors:  Young Mi Park; Hak Yong Lee; Dong Yeop Shin; Dae Sung Kim; Jin Joo Yoo; Hye Jeong Yang; Min Jung Kim; Jun Sang Bae
Journal:  Front Nutr       Date:  2022-05-19

Review 2.  Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Authors:  Kazuo Oshimi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

3.  Polysaccharide of Atractylodes macrocephala Koidz (PAMK) Relieves Immunosuppression in Cyclophosphamide-Treated Geese by Maintaining a Humoral and Cellular Immune Balance.

Authors:  Wanyan Li; Sixuan Guo; Danning Xu; Bingxin Li; Nan Cao; Yunbo Tian; Qingyan Jiang
Journal:  Molecules       Date:  2018-04-17       Impact factor: 4.411

4.  Protective Effect of Bergenin against Cyclophosphamide-Induced Immunosuppression by Immunomodulatory Effect and Antioxidation in Balb/c Mice.

Authors:  Qiuchen Qi; Zhonghua Dong; Yueyue Sun; Siying Li; Zhongxi Zhao
Journal:  Molecules       Date:  2018-10-17       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.